复发和未控卵巢恶性生殖细胞肿瘤保留生育功能的治疗
Preserve fertility in recurrent and uncontrolled malignant ovarian germ cell tumors

DOI: 10.6040/j.issn.1671-7554.0.2018.233

Keywords: 复发,未控,卵巢恶性生殖细胞肿瘤,化疗,挽救性手术,
Malignant ovarian germ cell tumor,Uncontrolled tumor,Recurrence,Chemoherapy,Salvage surgery

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Morris M, Gershenson DM, Burke TW, et al. Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide[J]. Obstet Gynecol, 1990, 76(6): 1020-1024.
[2]	Alcázar JL, Guerriero S, Pascual Má, et al. Clinical and sonographic features of uncommon primary ovarian malignancies[J]. J Clin Ultrasound, 2012, 40(6): 323-329.
[3]	Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group[J]. J Clin Oncol, 1994, 12(4): 701-706.
[4]	Li J, Wu X. Current strategy for the treatment of ovarian germ cell tumors role of extensive surgery[J]. Curr Treat Options in Oncol, 2016, 17(8): 44. doi: 10.1007/s11864-016-0416-2.
[5]	Munkarah A, Gershenson DM, Levenback C, et al. Salvage surgery for chemorefractory ovarian germ cell tumors[J]. Gynecol Oncol, 1994, 55(2): 217-223.
[6]	Mangili G, Sigismondi C, Gadducci A, et al. Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study[J]. Int J Gynecol Cancer, 2011, 21(8): 1414-1421.
[7]	Segelov E, Campbell J, Ng M, et al. Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience[J]. J Clin Oncol, 1994, 12(2): 378-384.
[8]	Dimopoulos MA, Papadimitriou C, Hamilos G, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study[J]. Gynecol Oncol, 2004, 95(3): 695-700.
[9]	Murugaesu N, Schmid P, Dancey G, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and longterm outcome after multimodality treatment[J]. J Clin Oncol, 2006, 24(30): 4862-4866.
[10]	中华医学会妇科肿瘤学分会. 妇科恶性肿瘤保留生育功能临床诊治指南[J]. 中华妇产科杂志, 2014, 49(4): 243-248.
[11]	Ertas IE, Taskin S, Goklu R, et al. Long-term oncological and reproductive outcomes of fertility-sparing cytoreductive surgery in females aged 25 years and younger with malignant ovarian germ cell tumors[J]. J Obstet Gynaecol Res, 2014, 40(3): 797-805.
[12]	Li J, Yang W, Wu X. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients[J]. Gynecol Oncol, 2007, 105(3): 769-775.
[13]	Yang ZJ, Liu ZC, Wei RJ, et al. An analysis of prognostic factors in patients with ovarian malignant germ cell tumors who are treated with fertility-preserving surgery[J]. Gynecol Obstet Invest, 2016, 81(1): 1-9.
[14]	Brown J, Friedlander M, Backes FJ, et al. Gynecologic cancer intergroup(GCIG)consensus review for ovarian germ cell tumors[J]. Int J Gynecol Cancer, 2014, 24(9 Suppl 3): S48-54.
[15]	Wang HB, Yang JX, Shen K, et al. Treatment of recurrent and persistent malignant ovarian germ cell tumors[J]. J Reprod Med, 2009, 18(S2): 64-68.
[16]	Dimopoulos MA, Papadopoulou M, Andreopoulou E, et al. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study[J]. Gynecol Oncol,1998, 70(1): 70-74.
[17]	Park JY, Kim DY, Suh DS, et al. Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors[J]. Gynecol Oncol, 2015, 137(3): 418-422.
[18]	Siriwan T, Jitti H, Sumonmal M, et al. Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes[J]. Acta Obstet Gynecol Scand, 2010, 89(2): 182-189.
[19]	Reddihalli PV, Subbian A, Umadevi K, et al. Immature teratoma of ovary—outcome following primary and secondary surgery: study of a single institution cohort[J]. Eur J Obstet Gynecol Reprod Biol, 2015, 192: 17-21. doi: 10.1016/j.ejogrb.2015.06.017. Epub 2015 Jun 25.
[20]	Liu Q,Ding X, Yang JX, et al. Multicenter randomized controlled clinical study for the operative treatment of malignant ovarian germ cell tumors[J]. Chin J Obstet Gynecol, 2013, 48(3): 188-192.
[21]	沈铿. 妇科恶性肿瘤保留生育功能治疗应注意的几个问题[J]. 中华妇产科杂志, 2006, 41(4): 219-221.
[22]	杨佳欣, 向阳. 复发性耐药性卵巢恶性生殖细胞肿瘤的治疗[J]. 中国实用妇科与产科杂志, 2015, 3(31): 201-211. YANG Jiaxin, XIANG Yang. Treatment of recurrent and uncontrolled malignant ovarian germ cell tumors[J]. Chin J Prac Gynecol Obstetr, 2015, 3(31): 201-211.
[23]	Rashdan S, Einhorn LH. Salvage therapy for patients with germ cell tumor[J]. J Oncol Pract, 2016, 12(5): 437-443.
[24]	Simone CG, Markham MJ, Dizon DS. Chemotherapy in ovarian germ cell tumors: a systematic review[J]. Gynecol Oncol, 2016, 141(3): 602-607.
[25]	Reddy Ammakkanavar N, Matei D, Abonour R, et al. High-dose chemotherapy for recurrent ovarian germ cell tumors[J]. J Clin Oncol, 2015, 33(2): 226-227.
[26]	De Giorgi U, Richard S, Badoglio M, et al. Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation(EBMT)[J]. Ann Oncol, 2017, 28(8):1910-1916.

Full-Text